<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04808570</url>
  </required_header>
  <id_info>
    <org_study_id>TQ-B3525-Ib/II-06</org_study_id>
    <nct_id>NCT04808570</nct_id>
  </id_info>
  <brief_title>A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</brief_title>
  <official_title>A Single-arm, Open-label, Multi-center Phase Ib/II Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the efficacy and safety of TQ-B3525 in subjects with&#xD;
      relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR) assessed by Independent Review Committee</measure>
    <time_frame>Baseline up to 18 months</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR) based on IRC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) assessed by Investigator</measure>
    <time_frame>Baseline up to 18 months</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR) assessed by investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of disease remission (DOR)</measure>
    <time_frame>Baseline up to 18 months</time_frame>
    <description>The time from the first evaluation of the subject as CR or PR to the first evaluation of the subject as PD or death (whichever occurs first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Baseline up to 18 months</time_frame>
    <description>PFS was defined as the time from the date of study enrollment to the date of the first of the following events, objective disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate（DCR）</measure>
    <time_frame>Baseline up to 18 months</time_frame>
    <description>Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>OS defined as the time from the first dose to death from any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events, Serious Adverse Events</measure>
    <time_frame>Baseline up to 18 months</time_frame>
    <description>AE, SAE, and withdrawal from the trial for reasons such as safety or tolerability.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>TQ-B3525 tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQ-B3525 tablet administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ-B3525 tablets</intervention_name>
    <description>TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.</description>
    <arm_group_label>TQ-B3525 tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Understood and signed an informed consent form; 2. 18 years and older, Eastern&#xD;
             Cooperative Oncology Group(ECOG) performance status score of 0 to 2, Life expectancy ≥&#xD;
             3 months; 3.Chronic lymphocytic leukemia/small lymphocytic lymphoma diagnosed by flow&#xD;
             cytometry or pathology, and meets at least one of the criteria for active diseases&#xD;
             requiring treatment in IWCLL2008; 4.Has received at least one line of previous&#xD;
             treatment, the latest treatment confirmed no objective response, or disease progress&#xD;
             after treatment; 5.Has at least one measurable lesion; 6. Adequate organ system&#xD;
             function; 7. Male or female subjects should agree to use an adequate method of&#xD;
             contraception starting with the first dose of study therapy through 6 months after the&#xD;
             last dose of study (such as intrauterine devices , contraceptives or condoms) ；No&#xD;
             pregnant or breastfeeding women, and a negative pregnancy test are received within 7&#xD;
             days before the first administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -1. Has Richter's transformation or prolymphocytic leukemia (PLL)； 2. Has central nervous&#xD;
        system violation; 3. Has uncontrolled primary autoimmune cytopenias, including autoimmune&#xD;
        hemolytic anemia (AIHA), idiopathic thrombocytopenic purpura (ITP), etc； 4. Has received&#xD;
        other PI3K inhibitors or CAR-T treatments; 5. Has diagnosed and/or treated additional&#xD;
        malignancy within 3 years prior to the first administration; 6.Diagnosed as type I diabetes&#xD;
        or uncontrollable type II diabetes, or fasting blood glucose&gt; 8.9 mmol/L or glycosylated&#xD;
        hemoglobin (HbA1c)&gt; 8.5% during the screening period; 7. Has interstitial lung disease or&#xD;
        drug-induced interstitial lung disease history; 8. Has a history of immunodeficiency&#xD;
        diseases; 9. Has multiple factors affecting oral medication; 10. Has adverse events caused&#xD;
        by previous therapy except alopecia that did not recover to ≤grade 1; 11. Has received&#xD;
        systemic steroid treatment within 7 days before the first administration; 12. Has received&#xD;
        other systemic anti-tumor medications within 4 weeks before the first administration, or&#xD;
        still within the 5 half-life of the medication, which occurs first; 13.Has active&#xD;
        infections within 4 weeks before the first administration; 14.Has received surgery, or&#xD;
        unhealed wounds within 4 weeks before the first administration; 15. Has a history of&#xD;
        autologous hematopoietic stem cell transplant within 3 months; 16. Has a history of&#xD;
        allogeneic hematopoietic stem cell transplant; 17. Grade II or higher cardiovascular&#xD;
        disease within 6 months before the first administration; 18.QTCF &gt; 480ms, LVEF &lt; 50%;&#xD;
        19.Urinary protein ≥ 2 +, and 24-hour urinary protein quantity&gt;1g within 7 days; 20. Has&#xD;
        active hepatitis B or C; 21. Has psychotropic substances abuse or a mental disorder; 22.&#xD;
        Has other conditions that make it inappropriate for the patient to be enrolled based on&#xD;
        investigator's opinion.&#xD;
&#xD;
        21. Has psychotropic substances abuse or a mental disorder;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Affiliate Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunyan Wang, Doctor</last_name>
      <email>wcy163@163.com</email>
    </contact>
    <investigator>
      <last_name>Chunyan Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou First People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shunqing Wang, Doctor</last_name>
      <email>drwangshq@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Shunqing Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Luo, Doctor</last_name>
      <email>luojungz@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Jun Luo, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jishi Wang, Doctor</last_name>
      <email>Wangjishi9646@163.com</email>
    </contact>
    <investigator>
      <last_name>Jishi Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongling Peng, Doctor</last_name>
      <email>577769365@163.com</email>
    </contact>
    <investigator>
      <last_name>Hongling Peng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianyong Li, Doctor</last_name>
      <email>lijianyonglm@126.com</email>
    </contact>
    <investigator>
      <last_name>Jianyong Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wei Xu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rong Fu, Doctor</last_name>
      <email>florai@sina.com</email>
    </contact>
    <investigator>
      <last_name>Rong Fu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Hospital of Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shuhua Yi, Doctor</last_name>
      <email>yishuhua@ihcams.ac.cn</email>
    </contact>
    <investigator>
      <last_name>Shuhua Yi, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yafei Wang, Doctor</last_name>
      <email>Prowyf08@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yafei Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>June 6, 2021</last_update_submitted>
  <last_update_submitted_qc>June 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

